Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients—The International Breast Cancer Study Group Trial VIII

Authors:
  • DZDavid Zahrieh
    David Zahrieh
  • MCMonica Castiglione-Gertsch
    Monica Castiglione-Gertsch
  • CHChristoph Hürny
    Christoph Hürny
  • RGRichard D. Gelber
    Richard D. Gelber
  • JFJohn F. Forbes
    John F. Forbes
  • EMElizabeth Murray
    Elizabeth Murray
  • JCJohn Collins
    John Collins
  • SAStefan Aebi
    Stefan Aebi
  • BTBeat Thürlimann
    Beat Thürlimann
  • KPKaren N. Price
    Karen N. Price
  • AGAron Goldhirsch
    Aron Goldhirsch
Publisher website
Google Scholar
Abstract
Purpose The purpose of this article is to compare quality of life (QOL) and menopausal symptoms among premenopausal patients with lymph node-negative breast cancer receiving chemotherapy, goserelin, or their sequential combination, and to investigate differential effects by age. Patients and Methods We evaluated QOL data from 874 pre- and perimenopausal women with lymph node-negative breast cancer who were randomly assigned to receive six courses of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy, ovarian suppression with goserelin for 24 months, or six courses of classical CMF followed by 18 months of goserelin. We report QOL data collected during 3 years after random assignment in patients without disease recurrence. Results Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF. There were no differences at 3 years after random assignment according to treatme...

This publication has 27 references indexed in Scilit: